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Abstract
Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most
commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in the prevention and
treatment of cardio-cerebrovascular diseases. Glycoprotein IIb/IIIa antagonists (e.g., abciximab, eptifibatide and
tirofiban) have demonstrated good clinical benefits and safety profiles in decreasing ischemic events in acute
coronary syndrome. However, adverse events related to thrombosis or bleeding have been reported in cases of
therapy with glycoprotein IIb/IIIa antagonists. Cilostazol is an anti-platelet agent used in the treatment of patients
with peripheral ischemia, such as intermittent claudication. Presently, platelet adenosine diphosphate P2Y(12)
receptor antagonists (e.g., clopidogrel, prasugrel, cangrelor, and ticagrelor) are being used in clinical settings for
their pronounced protective effects. The new protease-activated receptor antagonists, vorapaxar and atopaxar,
potentially decrease the risk of ischemic events without significantly increasing the rate of bleeding. Some other
new anti-platelet drugs undergoing clinical trials have also been introduced. Indeed, the number of new anti-
platelet drugs is increasing. Consequently, the efficacy of these anti-platelet agents in actual patients warrants
scrutiny, especially in terms of the hemorrhagic risks. Hopefully, new selective platelet inhibitors with high anti-
thrombotic efficiencies and low hemorrhagic side effects can be developed.
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Introduction
Thrombotic diseases and their complications may have
severe consequences. Platelets play a key role in throm-
bosis, and anti-platelet therapies may prevent as well as
treat thrombotic diseases. Therefore, anti-platelet drugs
that can inhibit platelet adhesion, aggregation, release,
and activation need to be developed (Figure 1). The
most commonly used anti-platelet drugs, namely,
aspirin, clopidogrel, and ticlopidine are effective in pre-
venting thrombotic diseases. With the developments in
medicine and pharmacy, the number of anti-platelet
agents is continuously increasing.
Platelet glycoprotein (GP) IIb/IIIa receptor
antagonists (Table 1)
The adhesion, aggregation, release, and activation of pla-
telets can induce platelet thrombosis, which is important
in physiological hemostasis and pathological thrombosis.
Once platelets are activated, GP IIb/IIIa receptors on
the surfaces of platelets transform into their active
states, which can combine with fibrinogen and the von
Willebrand factor (vWF). The GP IIb/IIIa receptor oper-
ates in the final common pathway of platelet aggrega-
tion. Blocking the GP IIb/IIIa receptor can inhibit
platelet aggregation induced by activating factors. Once
platelet aggregation is inhibited, platelet thrombi cannot
form.
The development of GP IIb/IIIa antagonists, such as
the recently approved abciximab, eptifibatide, and tirofi-
ban, is pivotal in anti-platelet therapy. Pharmacody-
namic studies on these three agents have revealed their
capabilities of establishing and maintaining a > 80%
inhibition of platelet aggregation [1].
The first GP IIb/IIIa receptor antagonist used in clini-
cal settings is abciximab. This drug is the fragment of
recombinant human-mouse chimeric monoclonal anti-
body, which can inhibit GP IIb/IIIa receptors in a dose-
dependent manner. Abciximab also inhibits aIIb/b3
receptors (for vWF) on platelets, thereby inhibiting pla-
telet aggregation via fibrinogen. However, abciximab
have the disadvantages of potential immunogenicity,
drug effect irreversibility, and high cost [2]. Hence,
micromolecular GP IIb/IIIa receptor antagonists (e.g.,
eptifibatide and tirofiban) have been developed. These
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the Arg-Gly-Asp (RGD) sequence. In the RGD sequence
of eptifibatide, an arginine residue is replaced by the
lysine residue. On the other hand, tirofiban is the micro-
molecular GP IIb/IIIa receptor antagonist synthesized
according to the RGD module. These micromolecular
agents, unlike abciximab, specifically act on GP IIb/IIIa
receptors and do not combine with any other integrin.
Eptifibatide and tirofiban also cannot induce immune
response given their small molecular weights and low
affinities to GP IIb/IIIa receptors.
Abciximab, eptifibatide, and tirofiban are all intrave-
nously injected. Large-scale clinical trials have demon-
strated the clear clinical effects and safety of these drugs
in decreasing the ischemic events in acute coronary syn-
drome (ACS). Their uses in adjunctive therapy during
percutaneous coronary intervention (PCI) have also
been revealed [3,4]. However, adverse events related to
thrombosis or bleeding have still been reported in cases
of therapy with GP IIb/IIIa [5]. Trials on orally adminis-
tered GP IIb/IIIa antagonists have failed to demonstrate
any benefit, and even indicated significantly increased
Figure 1 Different targets for anti-platelet therapy. According to the different targets, novel anti-platelet agents with different mechanism of
action can be developed, including GP IIb/IIIa antagonists, P2Y(12) receptor antagonists and Protease-activated receptor antagonists, etc.
Table 1 Glycoprotein IIb/IIIa antagonists
Agents Mechanism of action Administration Main side effects State
Abciximab inhibit GPIIb/IIIa receptor and GP aIIb/b3 receptor IV allergy, bleeding,
thrombocytopenia
Approved
Eptifibatide inhibit GPIIb/IIIa receptor IV bleeding,
thrombocytopenia
Approved
Tirofiban inhibit GP IIb/IIIa receptor IV bleeding,
thrombocytopenia
approved
Abbreviations: GP: glycoprotein; IV: intravenous.
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of GP IIb/IIIa antagonists needs further functional test-
ing methods to assess the anti-platelet efficacy of these
drugs in actual patients.
Agents that selectively increase cyclic adenosine
3’-5’-monophosphate (cAMP) in platelets
Platelet aggregation can be inhibited either by the block-
ing of membrane receptors or interaction with intracel-
lular signaling pathways. cAMP and cyclic guanosine 3’-
5-monophosphate (cGMP) are two important intracellu-
lar second messengers for platelet function. Phospho-
diesterase (PDE), which is obtained by catalyzing the
hydrolysis of cAMP and cGMP, limits the intracellular
levels of cyclic nucleotides to regulate platelet function.
Therefore, the inhibition of PDEs may confer a strong
inhibitory effect on platelets.
Cilostazol is an anti-platelet agent used in the treat-
ment of peripheral ischemia, such as intermittent claudi-
cation. This drug is a kind of selective inhibitor of
cAMP-PDE that can dilate blood vessels and hinder pla-
telet aggregation induced by adenosine diphosphate
(ADP), collagens and arachidonic acid. Unlike aspirin,
cilostazol is a reversible platelet inhibitor that prevents
both primary and secondary aggregation. In terms of
pharmacokinetics, cilostazol is metabolized in the liver
and excreted by the kidney.
Overall, cilostazol is a good drug of choice given its high
tolerance, small number of side effects, high safety, and
potential use with other anti-platelet drugs [7-9]. Cilosta-
zol may also be a more safer and effective alternative to
aspirin in the patients with ischemic stroke [10]. Presently,
there is a trend towards enhanced anti-platelet effects
when cilostazol is added to aspirin in the ischemic stroke
patients. A combination of aspirin and cilostazol may be a
good treatment option for these patients [11,12].
P2Y(12) receptor antagonists(Table 2)
P2Y(12) receptor antagonists are anti-thrombotic agents
that inhibit platelet function by blocking the ADP at
P2Y(12) receptor sites. Adenine nucleotides act on pla-
telets via three distinct P2 receptors, namely, two G pro-
tein-coupled ADP receptors, P2Y(1) and P2Y(12), as
well as a P2X(1) receptor ligand-gated cation channel
activated by adenosine triphosphate (ATP). The P2Y(1)
receptor initiates platelet aggregation, but is not suffi-
cient in response to ADP. On the other hand, the P2Y
(12) receptor is responsible for the completion of aggre-
gation in response to ADP. The P2Y(12) receptor is the
molecular target of anti-thrombotic drugs such as clopi-
dogrel, prasugrel, cangrelor, and ticagrelor. This recep-
tor is responsible for most of the potentiating effects of
ADP when platelets are activated by agonists such as
collagen, thrombin [13,14]. These platelet antagonists
blocking the ADP-receptor P2Y(12) decrease myocardial
infarction, stroke, thrombosis and mortality in the
patients with cardiovascular diseases. The P2Y(12)
antagonists (e.g., clopidogrel, prasugrel, and ticagrelor)
are now being used in clinical settings given their more
protective effects [15].
Presently, the P2Y(12) receptor antagonists being
developed are clopidogrel and prasugrel, which are thie-
nopyridines, as well as cangrelor and ticagrelor, which
are nonthienopyridines. Hence, these antagonists are
potential anti-thrombotic drugs.
Clopidogrel is a thienopyridine with proven antith-
rombotic efficacy. However, it has the disadvantages of
high inter-individual variability in pharmacological
response, delayed onset and offset of action, as well as
requiring to be metabolized to its active metabolite form
[16].
Prasugrel has received its priority right of approval in
2008. It is a new kind of thienopyridine P2Y12 receptor
antagonist that works by blocking the P2Y12 ADP
receptor on the surfaces of platelets. Nevertheless, the
clinical benefits of prasugrel are countered by increased
bleeding risk compared with the conventional thienopyr-
idine treatment using clopidogrel. In the clinical trial of
prasugrel versus clopidogrel in patients with acute cor-
onary syndromes (ClinicalTrials.gov number,
NCT00097591), the rates of myocardial infarction in the
prasugrel group were significantly reduced (9.7% for clo-
pidogrel vs. 7.4% for prasugrel; P < 0.001). There were
also significant reductions in the urgent target-vessel
revascularization (3.7% vs. 2.5%; P < 0.001), and stent
thrombosis (2.4% vs. 1.1%; P < 0.001). However, there
Table 2 P2Y(12) receptor antagonists
Agents Mechanism of action Administration Main Side effects State
Clopidogrel thienopyridine, blocking the effects of ADP at P2Y(12) receptor sites Oral bleeding,
thrombocytopenia
approved
Prasugrel thienopyridine, blocking the effects of ADP at P2Y(12) receptor sites Oral bleeding approved
Cangrelor nonthienopyridine, the blocking effects of ADP at P2Y(12) receptor
sites
IV bleeding unapproved
Ticagrelor nonthienopyridine, the blocking effects of ADP at P2Y(12) receptor
sites
Oral bleeding approved
Abbreviations: IV: intravenous; ADP:adenosine diphosphate.
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ing prasugrel (2.4%) than in patients receiving clopido-
grel (1.8%) (P = 0.03). The prasugrel group also had
greater rate of life-threatening bleeding (1.4% vs. 0.9%; P
= 0.01), including nonfatal bleeding (1.1% vs. 0.9%; P =
0.23) and fatal bleeding (0.4% vs. 0.1%; P = 0.002)[17].
Still, some current practice guidelines incorporate pra-
sugrel as a treatment option because it has a faster
onset of action and more uniform inhibition of platelet
function than clopidogrel. However, prasugrel is not
presently recommended to be selected over clopidogrel
in any patient subgroup. Further studies are required to
determine the optimal dosage and patient characteristics
for prasugrel treatments [18].
Two direct and reversible P2Y(12) antagonists, cangre-
lor and ticagrelor, are characterized by rapid onsets and
reversibilities of platelet inhibition.
Similar with the nonthienopyridine P2Y(12) receptor
antagonist, cangrelor is a reversible anti-platelet intrave-
nous preparation with a rapid effect because it can func-
tion without needing to be metabolized. In a study of
PCI patients, the use of cangrelor has shown no signifi-
cant difference compared with abciximab in major
adverse cardiac events and bleeding complications. Can-
grelor is only intravenously administrated. However,
there is no evidence that can prove its superiority over
current commonly used intravenous anti-platelet agents
(e.g., GP IIb/IIIa receptor antagonists such as abciximab)
in preventing thrombotic events in patients undergoing
PCI. Indeed, its therapeutic potential is uncertain [19].
On the other hand, ticagrelor is better than clopido-
grel in preventing major adverse cardiac events in ACS
patients. Compared with clopidogrel, ticagrelor
decreases the incidences of major adverse cardiac events
and thrombosis. Similar with prasugrel, ticagrelor is
associated with high frequencies of bleeding complica-
tions. A short period of drug discontinuation before sur-
gery is generally necessary in the ticagrelor-treated
patients in order to limit the risk of post-surgical bleed-
ing [20-23].
Protease-activated receptor (PAR) antagonists
(Table 3)
PARs include PARA1, PARA2, PARA3, and PARA4.
Similar with thrombin receptors, PAR1, PAR3, and
PAR4 mediate platelet activation induced by thrombin.
In humans, only PAR1 and PAR4 are expressed. The
ADP and thromboxane A2 (TXA2) platelet activation
pathways exist during the progress of pathological
thrombosis and physiological hemostasis. The combined
use of aspirin and clopidogrel well inhibits thrombosis
in induced hemorrhagic complications. PAR1-mediated
platelet activation mainly promotes pathological throm-
bosis and has less influence on protective hemostasis.
Hence, PAR1 antagonists decrease the incidence of
hemorrhagic complications [24,25]. Oral PAR1 antago-
nists currently being researched include vorapaxar (SCH
530348) and atopaxar (E-5555).
Vorapaxar, a synthetic tricyclic 3-phenylpyridine, is a
new orally active fourth generation himbacine-based
antagonist of the protease-activated receptor PAR1, and
is the primary receptor for thrombin in human platelets.
Vorapaxar is a non-peptide competitive PAR1 thrombin
receptor antagonist with a high affinity and low molecu-
lar weight. It belongs to the first agent in a new type of
compounds that inhibit thrombin-mediated platelet
aggregation without affecting the enzymatic activity of
thrombin on fibrinogen. Preclinical and initial clinical
studies have demonstrated the high potential of vora-
paxar in inhibiting thrombin-induced platelet activation,
as well as its excellent oral bioavailability and safety
[26]. Vorapaxar inhibits thrombin-mediated platelet
aggregation mediated, and does not influence hemostasis
as well as bleeding time. Hence, this drug potentially
decreases the risk for ischemic events without signifi-
cantly increasing the rate of bleeding. Vorapaxar, which
is orally administered, is rapidly absorbed and has a
long biological half-life [27,28].
Atopaxar is another powerful oral PAR1 antagonist.
Preclinical studies have indicated that atopaxar inhibits
thrombin-mediated platelet aggregation mediated with-
out increasing the rate of bleeding. The selective block-
ing of platelet receptors by atopaxar suggests its
therapeutic potential in thrombotic disease [29-31].
Novel anti-platelet drugs
The interaction between platelets and collagen is the
motivator of platelet adhesion, aggregation, and activa-
tion. This interaction has become the target for develop-
ing new anti-platelet agents. On the surfaces of platelets,
there exist at least three kinds of receptors that can
combine with collagen, including GP Ib/IX (functions
Table 3 Protease-activated receptor (PAR) antagonists
Agents Mechanism of action Administration Main side
effects
State
Vorapaxar a non-peptide competitivePAR1 thrombin receptor antagonist with a high affinity and
low molecular weight
oral bleeding unapproved
Atopaxar PAR1 antagonist inhibiting thrombin-mediated platelet aggregation oral bleeding unapproved
Abbreviations: PAR:protease-activated receptor.
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adhesion), and GPVI (mediates platelet activation). Pla-
telets adhesion to the damaged blood vessel is the initial
trigger for arterial hemostasis and thrombosis. Platelets
adhere to the sub-endothelium via their interaction with
the vWF, which forms a bridge between collagens within
the damaged vessel wall [32-34]. The development of
monoclonal antibodies that inhibit platelet adhesion or
aggregation targets collagen-vWF-GPIb and collagen-
GPVI [35-37].
The 6B4-antigen-binding fragment (Fab) is a murine
monoclonal antibody that targets the human platelet
GPIb alpha (201-268aa) and blocks the binding of the
vWF. It has been proved as a powerful anti-thrombotic
agent without the side effects of bleeding or thrombocy-
topenia. The anti-thrombotic effects of 6B4-Fab on
acute platelet-mediated thrombosis have been studied in
baboons. Minimal effects on the bleeding time, absence
of spontaneous bleeding, and absence of thrombocyto-
penia are observed. Hence, H6B4-Fab can be further
developed [38]. There are some other promising precli-
nical agents targeting GP Ib. Such agents include GPG-
290, a recombinant chimeric protein containing amino-
terminal 290 amino acids of alpha linked to the human
IgG1 crystallizable fragment, and Shuzhou2 (SZ2), an
anti-GP Ib monoclonal antibody [39].
The vWF plays an important role in both hemostasis
and thrombosis. Platelets adhere to damaged arteries by
the interactions between the vWF A1-domain and gly-
coprotein Ib receptors under conditions of high shear.
This initial platelet binding event stimulates platelet
activation, recruitment, and activation of the clotting
cascade, thereby promoting thrombus formation. There-
fore, the monoclonal antibody against the functional
domains (A1 and A3) of the vWF can effectively inhibit
thrombosis. The genetically engineered antibody
AJW200 is a humanized anti-vWF-A1 chimeric Fab
antibody that can block the combination of the vWF
and GP Ib. Consequently, platelet adhesion and aggrega-
tion are inhibited without remarkably prolonging the
bleeding time. The recombinant chimeric monoclonal
antibody 82D6A3 against the vWF-A3 region can block
the combination of the A3 region and collagen to inhibit
platelet adhesion. ARC1779, which has a high binding
affinity with the vWF A1-domain, has been proven to
inhibit botrocetin-induced and shear force-induced pla-
telet aggregation. Besides, ARC15105 is a chemically
advanced follower with a potential higher affinity to the
vWF [40,41].
GPVI, which is a major receptor of collagen on plate-
let surfaces, mediates the initial platelet contacting with
collagen, which can cause platelet adhesion, aggregation,
and thrombosis [42,43]. GPVI may be considered as an
interesting and prospective target in the development of
anti-platelet agents [44-46]. Anti-GPVI antibodies, such
as the monoclonal antibody JAQ1, can significantly pre-
vent thrombosis with a little prolonged bleeding time
[47].
Conclusions and future directions
Given the increasing incidence of and mortality from
thrombotic diseases, anti-platelet agents have been
extensively researched and developed [48,49]. The com-
bined use of anti-platelet drugs with different mechan-
isms may be important in anti-thrombotic treatments.
Further research on platelet functions may give rise to
numerous new anti-platelet agents. Pharmacodynamic
platelet function assays and pharmacokinetic tests for
individualizing and optimizing anti-platelet therapy may
find their way into clinical use. However, more studies
are needed. Hopefully, new selective platelet inhibitors
with high anti-thrombotic efficiencies and low adverse
hemorrhagic side affects can be developed.
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